GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Supernus Pharmaceuticals Inc (FRA:S49) » Definitions » Cyclically Adjusted PS Ratio

Supernus Pharmaceuticals (FRA:S49) Cyclically Adjusted PS Ratio : 3.33 (As of May. 22, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Supernus Pharmaceuticals Cyclically Adjusted PS Ratio?

As of today (2024-05-22), Supernus Pharmaceuticals's current share price is €26.20. Supernus Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 was €7.87. Supernus Pharmaceuticals's Cyclically Adjusted PS Ratio for today is 3.33.

The historical rank and industry rank for Supernus Pharmaceuticals's Cyclically Adjusted PS Ratio or its related term are showing as below:

FRA:S49' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 2.93   Med: 5.48   Max: 10.58
Current: 3.32

During the past years, Supernus Pharmaceuticals's highest Cyclically Adjusted PS Ratio was 10.58. The lowest was 2.93. And the median was 5.48.

FRA:S49's Cyclically Adjusted PS Ratio is ranked worse than
66.71% of 742 companies
in the Drug Manufacturers industry
Industry Median: 2.13 vs FRA:S49: 3.32

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Supernus Pharmaceuticals's adjusted revenue per share data for the three months ended in Mar. 2024 was €2.376. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €7.87 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Supernus Pharmaceuticals Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Supernus Pharmaceuticals's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Supernus Pharmaceuticals Cyclically Adjusted PS Ratio Chart

Supernus Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.13 5.82 5.27 5.09 3.49

Supernus Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.91 3.90 3.42 3.49 3.94

Competitive Comparison of Supernus Pharmaceuticals's Cyclically Adjusted PS Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Supernus Pharmaceuticals's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Supernus Pharmaceuticals's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Supernus Pharmaceuticals's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Supernus Pharmaceuticals's Cyclically Adjusted PS Ratio falls into.



Supernus Pharmaceuticals Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Supernus Pharmaceuticals's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=26.20/7.87
=3.33

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Supernus Pharmaceuticals's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Supernus Pharmaceuticals's adjusted Revenue per Share data for the three months ended in Mar. 2024 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.376/131.7762*131.7762
=2.376

Current CPI (Mar. 2024) = 131.7762.

Supernus Pharmaceuticals Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201406 0.515 100.560 0.675
201409 0.410 100.428 0.538
201412 0.590 99.070 0.785
201503 0.591 99.621 0.782
201506 0.608 100.684 0.796
201509 0.680 100.392 0.893
201512 0.779 99.792 1.029
201603 0.776 100.470 1.018
201606 0.888 101.688 1.151
201609 0.974 101.861 1.260
201612 1.137 101.863 1.471
201703 1.020 102.862 1.307
201706 1.268 103.349 1.617
201709 1.258 104.136 1.592
201712 1.396 104.011 1.769
201803 1.363 105.290 1.706
201806 1.572 106.317 1.948
201809 1.627 106.507 2.013
201812 1.884 105.998 2.342
201903 1.401 107.251 1.721
201906 1.719 108.070 2.096
201909 1.724 108.329 2.097
201912 1.687 108.420 2.050
202003 1.604 108.902 1.941
202006 2.098 108.767 2.542
202009 2.450 109.815 2.940
202012 2.195 109.897 2.632
202103 2.029 111.754 2.393
202106 2.144 114.631 2.465
202109 2.323 115.734 2.645
202112 2.582 117.630 2.893
202203 2.255 121.301 2.450
202206 2.620 125.017 2.762
202209 3.255 125.227 3.425
202212 2.544 125.222 2.677
202303 2.300 127.348 2.380
202306 2.296 128.729 2.350
202309 2.640 129.860 2.679
202312 2.725 129.419 2.775
202403 2.376 131.776 2.376

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Supernus Pharmaceuticals  (FRA:S49) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Supernus Pharmaceuticals Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Supernus Pharmaceuticals's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Supernus Pharmaceuticals (FRA:S49) Business Description

Traded in Other Exchanges
Address
9715 Key West Avenue, Rockville, MD, USA, 20850
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. The Company's diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Supernus Pharmaceuticals (FRA:S49) Headlines

No Headlines